References
Preskorn SH. Duloxetine. J Psychiatr Pract 2004; 10: 375–85.
Gross CM, Klöcker M, Jakob T, Klecha D. Dermatological side effects during therapy with serotonin noradrenaline reuptake inhibitors. Nervenarzt 2008; 79: 1307–9.
Vey EL, Kovelman I. Adverse events, toxicity and post-mortem data on duloxetine: case reports and literature survey. J Forensic Leg Med 2010; 17: 175–85.
Mallinckrodt CH, Prakash A, Andorn AC. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006; 40: 337–48.
Strawn JR, Whitsel R, Nandagopal JJ, Delbello MP. Atypical Stevens-Johnson syndrome in an adolescent treated with duloxetine. J Child Adolesc Physchopharmacol 2011; 21: 91–2.
Begaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985; 40: 111–8.
Arimone Y, Bidault I, Dutertre J-P. Update of the French drug reaction assessment method. Therapie 2011; 66: 517–25.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Erfan, G., Alp, R., Albayrak, S. et al. Leukocytoclastic vasculitis due to duloxetine. Eur J Dermatol 25, 194–195 (2015). https://doi.org/10.1684/ejd.2014.2491
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2014.2491